INTRODUCTION
Lymphoma comprises a heterogeneous collection of lymphoproliferative malignancies with varying clinical behavior and response profiles. These disorders are commonly categorized as either Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL), with the latter group constituting the vast majority of cases. HL tends to be less aggressive in nature and carries a relatively high 5-year survival rate of 85.3% (1) . In 2015, this subtype of lymphoma was diagnosed in an estimated 9,050 patients and caused 1,150 deaths in the United States (2) . By comparison, NHL includes dozens of distinct conditions with varying etiologies and prognoses. The nodular enlargements characteristic of lymphoma were noted in the medical literature as early as 1661 (5), but the constellation of "lymph node and spleen enlargement, cachexia and fatal termination" was first described by Thomas Hodgkin in 1832 (6). The development of modern treatments occurred over a century later, when the discovery of marked lymphoid and myeloid suppression in soldiers exposed to mustard gas during the Second World War led Louis S. Goodman and Alfred Gilman to test the effects of a related compoundnitrogen mustard-on patients with lymphoma and other hematological diseases (7).
Even these early chemotherapeutic agents required an objective means of evaluating their in vivo effectiveness in human subjects. Initially, standardized methods for the manual measurement of tumor size pre-and post-therapy were proposed for this purpose. But as anatomical medical imaging techniques, most notably computed tomography (CT), became available, an array of novel guidelines for response assessment were developed. More recently, functional information from positron emission tomography (PET) has been integrated to complement the anatomical information of CT. Currently, numerous response assessment criteria that rely on CT and PET individually, as well as a handful of criteria that combine these imaging modalities, have been reported for assessing treatment response in both solid tumors and hematologic malignancies (Supplemental Table 1 ). Although recent progress has been made towards the standardization of response assessment, the clinical and research communities remain somewhat fragmented in their use of these various criteria. This review article outlines the available criteria and highlights what differentiates them in an attempt to facilitate a more uniform approach to response assessment.
HISTORICAL REVIEW OF RESPONSE ASSESSMENT IN SOLID TUMORS
From the development of the first chemotherapeutic agents in the 1940s to the advent of modern imaging techniques in the 1970s, objective and systematic assessment of treatment response depended largely on physical examination (8). However, palpation as a method of assessing response was imprecise, as demonstrated by a 1976 study by Moertel and Hanley in which sixteen oncologists palpated and measured twelve simulated tumor masses using "variable clinical methods" (9). The authors found that criteria that defined response as 25% and 50% reductions in the perpendicular diameters of these palpated tumors resulted in false positive readings in 19-25% and 6.8-7.8% of cases, respectively.
With the goal of achieving "the standardization of reporting results of cancer treatment," the WHO held a series of meetings between 1977 and 1979 that culminated in the publication of a handbook outlining response assessment criteria that were widely publicized and rapidly adopted (10,11). The criteria called for bi-dimensional tumor measurements to be obtained prior to and following therapy, and the product of these bi-dimensional measurements to be calculated and summed across several sites of disease to form a single parameter with which to assess response. The changes in these parameters over time classified patients into one of four response groups: complete response (CR), partial response (PR), no response (NR), and progressive disease (PD) (Supplemental Table 2 ).
Although these guidelines made strides toward standardization of response assessment, they did not explicitly specify critical factors, including the number of masses to be measured and the minimum measureable size of a tumor (12). As a result of these ambiguities, as well as the introduction of imaging modalities such as CT, the WHO criteria eventually became the subject of reinterpretation by various research organizations and clinical groups, thus undermining the standardization it was designed to promote.
In order to address the gradual divergence of response assessment, institutions such as the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from Cancer (EORTC) began revisiting the WHO criteria throughout the 1990s with the goal of developing new guidelines that would re-standardize the practice of evaluating response to therapy. In 1999, the EORTC released its own recommendations for patient preparation prior to imaging, image acquisition and analysis, tumor sampling, and classification of tumor response (13). These were among the first guidelines to employ a functional imaging modality, namely PET, as a means of assessing treatment response (Supplemental Table 3 ). The PET radiotracer The incorporation of PET imaging helped to address the issue of residual masses detected after therapy, which frequently comprise inflammatory, necrotic, and fibrotic tissue rather than residual disease (14-16). This phenomenon proved especially problematic for response assessment criteria for lymphoma that relied solely on anatomic imaging. Approximately 40% of NHL patients and 20% of HL patients continue to exhibit residual mediastinal or abdominal masses on CT following therapy (17, 18) . In studies where such patients were restaged via laparotomy, between 80% and 95% of residual masses were shown to be non-malignant on pathology (17, 19) . Moreover, the presence of residual masses on imaging was not found to be associated with time to relapse or survival (18) . Therefore, by shedding light on the metabolic activity and thereby viability of these masses, PET overcame a significant limitation of CT-based response assessment for lymphoma (20).
In 2000, shortly after the EORTC devised its PET-based criteria, a collaboration between the NCI and EORTC provided a new set of CT-based guidelines called Response Evaluation Criteria In Solid Tumors (RECIST) (21). Unlike earlier anatomic criteria (11,22), RECIST assessed tumor response on the basis of unidimensional measurements made on CT along the tumor's longest axis, rendering the process more reproducible and applicable to the clinical setting. RECIST also defined the parameters that had been the source of disagreement between groups implementing the WHO criteria; the maximum number of lesions to be measured was set at ten, with a maximum of five per organ, and the minimum size of a lesion to be measured was set at one cm. Finally, RECIST redefined the response categories that were established in the WHO criteria (Table 1) . These reformulated classifications were conservative relative to the WHO criteria, placing fewer patients in the progressive disease category (21,23,24).
However, RECIST was not without shortcomings. It was widely reported to be less suitable for particular cancers, such as mesothelioma and pediatric tumors (23,25,26).
Furthermore, the arbitrary number of tumor foci to be measured according to the criteria and the relatively narrow definition of progressive disease were points of contention (27). It was also suggested that the routine clinical implementation of RECIST would significantly increase the workload of radiologists (28).
To address these limitations, the RECIST Working Group set out to amend the criteria, publishing "RECIST 1. sets it apart. The authors stated that CT alone possesses "poor predictive ability" because the residual masses that are detected by this modality often reflect scarring that is mistaken for active tumor. As a PET-based criteria for response assessment, PERCIST was "designed to facilitate trials of drug development, but, if sufficiently robust, could be applied to individual patients" (12).
In their report outlining PERCIST, Wahl et al specified a host of parameters that would facilitate the standardization of PET-based response assessment once the criteria was widely adopted. Among these suggestions was a proposed maximum of 5 tumor foci of the highest 18F-FDG avidity, with up to 2 foci per organ, to be measured for comparison before and after therapy. It was also recommended that patients undergo 18F-FDG-PET scans at least 10 days after an early cycle of chemotherapy in order to maximize the prognostic value of the scan and minimize the effect of 18F-FDG-avid inflammation caused by chemotherapy and radiation.
Moreover, the authors called for the standardized uptake values (SUVs) derived from a PET scan to be corrected for lean body mass (SUL) and compared to reference uptake in the liver or, if necessary, background blood pool (12). Finally, PERCIST retained the same four response classifications that were established in RECIST, but amended their respective specifications (Table 2 ).
Although not yet fully validated, the PERCIST criteria are increasingly used in clinical trials for assessing therapy response in cancer (Bai et al, Theranostics. 2013 Oct 7;3(10):787-801). Such data will potentially help support its more widespread clinical application.
MODERN RESPONSE ASSESSMENT CRITERIA IN LYMPHOMA
While the guidelines included in the WHO criteria, RECIST, and PERCIST are generalizable to a wide array of cancers, a number of specialized criteria have also been proposed specifically for the spectrum of hematological malignancies. As early as the late-1980s, as guidelines began to be developed for response assessment in chronic lymphocytic leukemia (CLL) (35), Hodgkin lymphoma (HL) (36), and acute myelogenous leukemia (AML) (37), there were calls for similar efforts toward standardization in NHL (38). However, in the decade that followed, various organizations simply adapted existing criteria to create their own guidelines for response assessment in NHL, thereby hindering the ability to compare data across different groups.
At meetings sponsored by the NCI in February and May 1998, an international working group, which comprised both American and European experts, reached a consensus on response assessment criteria specifically for NHL by (39). The resulting International Working Criteria (IWC) defined anatomic parameters, obtained by clinical or radiological exam, that could be used to group patients into the traditional classifications of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), as well a new classification of "unconfirmed complete response" (CRu) ( Table 3) . To support these anatomically-based criteria, the IWC defined the upper limit of a normal lymph node size as one cm along its short axis on the basis of several prior studies (40-42). In the years following its publication, the IWC were also adopted for HL (43) . in their greatest transverse diameters, mediastinal blood pool activity was recommended as a reference. On the other hand, for residual masses smaller than 2 cm, background activity was the recommended reference. Residual hepatic and splenic lesions larger than 1.5 cm detected on CT were deemed positive if their metabolic activity was higher than that of the liver and spleen.
These amendments permitted the elimination of the CRu category of tumor response, returning the classification scheme to the classic tetrad of CR, PR, SD, and PD (Table 4 ).
An international workshop that first met in Deauville, France in 2009 conceived of novel criteria for both HL and NHL that signaled a significant change on multiple fronts (46) (47) (48) (49) . In contrast to the predominantly quantitative guidelines proposed previously, the Deauville fivepoint scoring system (D5PS) assessed treatment response qualitatively, specifically in the form of a 5-point scale that graded the intensity of 18 F-FDG uptake relative to the reference activity of the mediastinal blood pool and liver (Table 5) 
METHODOLOGICAL COMPARISON OF EXISTING RESPONSE ASSESSMENT

CRITERIA
The various therapy response criteria discussed in this review employ varying approaches in the use of imaging modalities such that the RECIST and 1999 IWC criteria primarily utilize CT, while EORTC and PERCIST rely on PET, and the 2007 IWC and Lugano classifications make use of both modalities with the former using IHP and the latter the D5PS criteria for PET interpretation. The assorted definitions of the response classifications across these criteria are shown in Table 7 , which presents a simplified and standardized scheme comprising four groupings: CR, PR, SD, and PD. Although there are identifiable trends across criteria, even those employing the same modality demonstrate considerable variability in their thresholds for each response classification. For example, progressive disease is defined as a ≥20% increase in tumor size by RECIST, a ≥25% increase by the WHO criteria, and a ≥50% increase by IWC.
In recent years, the relative simplicity of the D5PS and the associated Lugano 
FUTURE TRENDS
The recent advent and adoption of the D5PS and Lugano classification have marked a step towards standardization of interpretation and brought a relatively more objective system. However, this qualitative response assessment system should also be tested against quantitative criteria to determine their relative effectiveness in patient management. In an earlier study, the tradeoff between simplicity and reproducibility was studied by Lin et al, who compared the prognostic ability of qualitative and quantitative PET analysis in patients with diffuse large Bcell lymphoma (DLBCL) (59). Visual analysis was able to predict event-free survival with an accuracy of 65.2%, whereas SUV-based analysis did so with an accuracy of 76.1%. A reduction of 65.7% in the maximal SUV of an interim PET scan was found to be the optimal cutoff value in differentiating between favorable and unfavorable responses to therapy. These earlier results suggest that, if optimized for clinical use, standardized PET criteria employing a quantitative method may be more adept at assessing tumor response. However, various study biases and suboptimal technical methodology inherent in retrospective design of prior studies , make it difficult to arrive at a firm conclusion. Moreover, multiple factors, including differences in instrumentation, scanner calibration, variable human biology, complicates obtaining reliable PET measurements across medical centers in future studies [Bai et al, Theranostics. 2013 Oct 7;3(10):787-801]. Thus, the most reproducible and accurate method for PET quantification remains to be determined. As techniques for automated segmentation and quantification continue to improve, these advancements will likely be more readily implemented in the clinical setting and facilitate the use of quantitative response assessment.
CONCLUSION
Over the past six decades, the techniques employed for evaluating the efficacy of cancer therapies have steadily increased both the precision and intricacy, moving from crude manual measurement towards more complex structural and functional data acquisition, with many more advanced techniques such as heterogeneity measures, and advanced parametric mapping and kinetic acquisitions/modeling on the way. The integration of CT and PET in particular greatly enhanced the ability to assess disease progression, adjust therapeutic regimens, and form an accurate prognosis. However, the vast array of interpretative guidelines that were introduced, each with their own protocols and thresholds, created stifling methodological variability and sparked calls for "harmonization" that have rung out since the early days of response assessment and continue to echo to this day (60). 
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